Compare PESI & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PESI | CERS |
|---|---|---|
| Founded | 1990 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Environmental Services | EDP Services |
| Sector | Industrials | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 243.9M | 276.0M |
| IPO Year | 1996 | 1996 |
| Metric | PESI | CERS |
|---|---|---|
| Price | $13.00 | $1.68 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 119.4K | ★ 1.8M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 27.27 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $60,030,000.00 | $51,326,000.00 |
| Revenue This Year | $9.91 | $20.00 |
| Revenue Next Year | $62.48 | $9.60 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 30.68 |
| 52 Week Low | $6.25 | $1.12 |
| 52 Week High | $16.50 | $2.96 |
| Indicator | PESI | CERS |
|---|---|---|
| Relative Strength Index (RSI) | 40.94 | 30.96 |
| Support Level | $12.40 | $1.37 |
| Resistance Level | $14.80 | $1.72 |
| Average True Range (ATR) | 0.79 | 0.16 |
| MACD | -0.09 | -0.08 |
| Stochastic Oscillator | 27.08 | 6.60 |
Perma-Fix Environmental Services Inc is a provider of both nuclear services and the management of nuclear and mixed waste. The company operates through two segments: The treatment segment offers nuclear, low-level radioactive, Mixed, hazardous and non-hazardous waste treatment, processing and disposal services, and the Services segment which generates the majority of the revenue, provides on-site waste management services to commercial and government customers, technology-based services, construction, logistics, and transportation services among others.
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.